Table 8.
Multivariable analysis of OS and DFS in patients received NAC (n = 78)
| Variable | OS | DFS | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P value | HR | 95%CI | P value | |
| CMTM1_v17 | ||||||
| High vs low | 3.642 | 1.594–8.324 | 0.002 | 3.094 | 1.507–6.350 | 0.002 |
| Pathological stage | ||||||
| III vs I/II | 2.862 | 1.316–6.224 | 0.008 | 2.704 | 1.315–5.560 | 0.007 |
| Gender | ||||||
| Male vs female | 1.026 | 0.399–2.636 | 0.958 | |||
| Histology | ||||||
| Adenocarcinoma vs non-Adenocarcinoma | 2.038 | 0.879–4.727 | 0.097 | |||
P value was calculated using a two-sided log-rank test
OS overall survival, DFS disease-free survival, HR hazard ratio (log-rank), CI confidence interval.
Bold values are significant (P < 0.05)